Metformin is the 1st line treatment in all subjects with type 2 diabetes without a contraindication to its use. The compliance with the use of metformin is not optimal mainly owing to relatively frequent gastrointestinal side effects. However, hard data about the real compliance are currently not available. In this trial we aim at assessing the compliance with metformin intake using a combination of serum metformin measurement and a specific questionnaire. We will further evaluate the impact of different pharmacological forms of metformin (standard vs. XR - extended release) on its compliance and try to identify common characteristics associated with reduced compliance.
Study Type
OBSERVATIONAL
Enrollment
400
Subjects on chronic metformin therapy will have their plasma metformin levels measured during a regular check-up with glycated hemoglobin assessment.
Institute for Clinical and Experimental Medicine
Prague, Czechia
RECRUITINGPlasma metformin levels
Time frame: At the time of measurement
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.